RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0
|
作者：
Nakahara, Yoshiro [1 ]
Hosomi, Yukio [1 ]
Yomota, Makiko [1 ]
Okuma, Yusuke [1 ]
Takagi, Yusuke [1 ]
Iguchi, Mari [1 ]
Okamura, Tatsuru [1 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
wild-type EGFR; Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-034
引用
下载
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [41] PREDICTIVE BIOMARKERS IN NSCLC PATIENTS TREATED WITH ERLOTINIB AFTER CHEMOTHERAPY: EGFR EXPRESSION OR MUTATIONS?
    Inno, A.
    Maci, E.
    Martini, M.
    Arena, V.
    Di Noia, V. P.
    Schinzari, G.
    Larocca, L. M.
    Cassano, A.
    Pozzo, C.
    Barone, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 433 - 433
  • [42] Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression
    Rivera-Soto, Ricardo
    Henley, Benjamin
    Pulgar, Marian A.
    Lehman, Stacey L.
    Gupta, Himanshu
    Perez-Vale, Kia Z.
    Weindorfer, Megan
    Vijayaraghavan, Smruthi
    Yao, Tsun-Wen Sheena
    Laquerre, Sylvie
    Moores, Sheri L.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [43] Second line treatment for EGFR wild-type advanced NSCLC: The Jury is Still Out
    Dafni, U.
    Karlis, D.
    Smit, E.
    Peters, S.
    LUNG CANCER, 2014, 84 (03) : 314 - 315
  • [44] OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR.
    Li, Kai
    Han, Baohui
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Li, Baolan
    Wang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR
    Tao Li
    Qi Xie
    Yang-Yang Fang
    Yi Sun
    Xiao Ming Wang
    Zhu Luo
    Gui-Ling Yan
    Jian-Bo He
    Xiao-Qun Zheng
    BMC Cancer, 23
  • [46] EGFR WILD-TYPE NSCLC PATIENTS WITH HIGH MIR-200C EXPRESSION CAN BENEFIT FROM EGFR-TKI
    Li, Jiayu
    Li, Xuefei
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S133 - S133
  • [47] Erlotinib Potentiates Cetuximab-dependent Cell Citotoxicity in Egfr Wild Type Nsclc Cell Lines
    Cavazzoni, A.
    Alfieri, R. R.
    La Monica, S.
    Galetti, M.
    Bonelli, M.
    Fumarola, C.
    Galvani, E.
    Tiseo, M.
    Ardizzoni, A.
    Petronini, P. G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S246 - S246
  • [48] Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
    Ulivi, Paola
    Delmonte, Angelo
    Chiadini, Elisa
    Calistri, Daniele
    Papi, Maximilian
    Mariotti, Marita
    Verlicchi, Alberto
    Ragazzini, Angela
    Capelli, Laura
    Gamboni, Alessandro
    Puccetti, Maurizio
    Dubini, Alessandra
    Burgio, Marco Angelo
    Casanova, Claudia
    Crino, Lucio
    Amadori, Dino
    Dazzi, Claudio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (01): : 747 - 757
  • [49] EGFRVIII ACTIVATES A DISTINCT PATHWAY THAN WILD-TYPE EGFR BUT THE FINAL DECISION BELONGS TO WILD-TYPE EGFR
    Treda, Cezary
    Stoczynska-Fidelus, Ewelina
    Piaskowski, Sylwester
    Grzela, Dawid
    Zieba, Jolanta
    Walczak, Maciej
    Banaszczyk, Mateusz
    Peciak, Joanna
    Rieske, Piotr
    ANTICANCER RESEARCH, 2014, 34 (10) : 6216 - 6217
  • [50] EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib
    Larsen, Anne Winther
    Nissen, Peter Henrik
    Meldgaard, Peter
    Weber, Britta
    Sorensen, Boe Sandahl
    LUNG CANCER, 2014, 85 (03) : 435 - 441
12345